This Chorionic Gonadotropin market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to increased awareness of hCG among healthcare professionals and patients, greater utilization for treating hormonal imbalance disorders, enhanced affordability, improvements in healthcare facilities, and a rising demand for assisted reproduction.
Market growth during the forecast period is expected to be driven by the increasing prevalence of infertility issues, rising awareness of reproductive health, greater adoption of assisted reproductive technologies, a higher incidence of hypogonadism among the elderly, and the expansion of healthcare infrastructure. Major trends in the forecast period include technological advancements, progress in recombinant technology, growth in assisted reproductive technologies, investments in research and development, and innovations in drug delivery systems and formulations.
Increasing prevalence of infertility issues is expected to drive the growth of the chorionic gonadotropin (hCG) market. Infertility is defined as the inability to conceive after one year of regular, unprotected intercourse for couples under 35, or after six months for those 35 and older. The rise in infertility is attributed to delayed childbearing, as many individuals choose to have children later in life, as well as lifestyle factors like obesity and smoking, which negatively impact reproductive health. Chorionic gonadotropin is used in fertility treatments to induce ovulation, support the luteal phase, and stimulate testosterone production in men. For example, the World Health Organization (WHO) reported in April 2023 that 17.5% of the adult population, or 1 in 6 people globally, experience infertility, highlighting the growing demand for fertility treatments. Therefore, the increasing prevalence of infertility issues is driving the growth of the chorionic gonadotropin market.
An increase in assisted reproductive technologies (ART) is expected to propel the growth of the chorionic gonadotropin market. ART includes medical procedures like in-vitro fertilization (IVF) that help individuals or couples achieve pregnancy. The rise in ART is driven by higher infertility rates, medical advancements, and delayed childbearing. Chorionic gonadotropin plays a crucial role in ART by triggering ovulation and supporting the luteal phase after embryo transfer. According to MJH Life Sciences, the number of ART cycles performed increased significantly, with egg freezing cycles rising from 24,560 in 2021 to 29,803 in 2022. As ART continues to expand, the demand for chorionic gonadotropin is also expected to grow.
A key trend in the chorionic gonadotropin market is the development of innovative solutions, such as saliva-based pregnancy tests, to improve convenience, accuracy, and accessibility. Saliva-based pregnancy tests detect the presence of hCG in saliva, offering a non-invasive and more comfortable alternative to traditional urine-based tests. In June 2023, Salignostics, an Israel-based biotech company, launched the world’s first saliva-based pregnancy test, Salistick. This product enables women to determine pregnancy using a saliva sample, with results available in 5 to 15 minutes, providing a more convenient and discreet testing experience.
Key player operating in the chorionic gonadotropin market is Ferring Pharmaceuticalss.
North America was the largest region in the chorionic gonadotropin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chorionic gonadotropin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chorionic gonadotropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chorionic gonadotropin, specifically human chorionic gonadotropin (hCG), is a hormone produced by the placenta during pregnancy. It helps maintain progesterone levels by supporting the corpus luteum. hCG is used in medical treatments to induce ovulation in women, treat hypogonadism in men, and as a tumor marker for certain cancers.
The primary types of chorionic gonadotropin are human chorionic gonadotropin and animal chorionic gonadotropin. Human chorionic gonadotropin (hCG) is primarily produced during pregnancy by cells in the placenta, which nourish the fertilized egg after it attaches to the uterine wall. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for therapeutic applications such as male hypogonadism, female infertility treatment, oligospermic treatment, cryptorchidism treatment, chronic pain, and others. End users include research institutions and pharmaceutical companies.
The chorionic gonadotropin market research report is one of a series of new reports that provides chorionic gonadotropin market statistics, including chorionic gonadotropin industry global market size, regional shares, competitors with a chorionic gonadotropin market share, detailed chorionic gonadotropin market segments, market trends and opportunities, and any further data you may need to thrive in the chorionic gonadotropin industry. This chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chorionic gonadotropin market consists of sales of products including follicle-stimulating hormone, luteinizing hormone, menotropins, gonadotropin-releasing hormone, and clomiphene citrate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to increased awareness of hCG among healthcare professionals and patients, greater utilization for treating hormonal imbalance disorders, enhanced affordability, improvements in healthcare facilities, and a rising demand for assisted reproduction.
Market growth during the forecast period is expected to be driven by the increasing prevalence of infertility issues, rising awareness of reproductive health, greater adoption of assisted reproductive technologies, a higher incidence of hypogonadism among the elderly, and the expansion of healthcare infrastructure. Major trends in the forecast period include technological advancements, progress in recombinant technology, growth in assisted reproductive technologies, investments in research and development, and innovations in drug delivery systems and formulations.
Increasing prevalence of infertility issues is expected to drive the growth of the chorionic gonadotropin (hCG) market. Infertility is defined as the inability to conceive after one year of regular, unprotected intercourse for couples under 35, or after six months for those 35 and older. The rise in infertility is attributed to delayed childbearing, as many individuals choose to have children later in life, as well as lifestyle factors like obesity and smoking, which negatively impact reproductive health. Chorionic gonadotropin is used in fertility treatments to induce ovulation, support the luteal phase, and stimulate testosterone production in men. For example, the World Health Organization (WHO) reported in April 2023 that 17.5% of the adult population, or 1 in 6 people globally, experience infertility, highlighting the growing demand for fertility treatments. Therefore, the increasing prevalence of infertility issues is driving the growth of the chorionic gonadotropin market.
An increase in assisted reproductive technologies (ART) is expected to propel the growth of the chorionic gonadotropin market. ART includes medical procedures like in-vitro fertilization (IVF) that help individuals or couples achieve pregnancy. The rise in ART is driven by higher infertility rates, medical advancements, and delayed childbearing. Chorionic gonadotropin plays a crucial role in ART by triggering ovulation and supporting the luteal phase after embryo transfer. According to MJH Life Sciences, the number of ART cycles performed increased significantly, with egg freezing cycles rising from 24,560 in 2021 to 29,803 in 2022. As ART continues to expand, the demand for chorionic gonadotropin is also expected to grow.
A key trend in the chorionic gonadotropin market is the development of innovative solutions, such as saliva-based pregnancy tests, to improve convenience, accuracy, and accessibility. Saliva-based pregnancy tests detect the presence of hCG in saliva, offering a non-invasive and more comfortable alternative to traditional urine-based tests. In June 2023, Salignostics, an Israel-based biotech company, launched the world’s first saliva-based pregnancy test, Salistick. This product enables women to determine pregnancy using a saliva sample, with results available in 5 to 15 minutes, providing a more convenient and discreet testing experience.
Key player operating in the chorionic gonadotropin market is Ferring Pharmaceuticalss.
North America was the largest region in the chorionic gonadotropin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in chorionic gonadotropin report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the chorionic gonadotropin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Chorionic gonadotropin, specifically human chorionic gonadotropin (hCG), is a hormone produced by the placenta during pregnancy. It helps maintain progesterone levels by supporting the corpus luteum. hCG is used in medical treatments to induce ovulation in women, treat hypogonadism in men, and as a tumor marker for certain cancers.
The primary types of chorionic gonadotropin are human chorionic gonadotropin and animal chorionic gonadotropin. Human chorionic gonadotropin (hCG) is primarily produced during pregnancy by cells in the placenta, which nourish the fertilized egg after it attaches to the uterine wall. It is distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, for therapeutic applications such as male hypogonadism, female infertility treatment, oligospermic treatment, cryptorchidism treatment, chronic pain, and others. End users include research institutions and pharmaceutical companies.
The chorionic gonadotropin market research report is one of a series of new reports that provides chorionic gonadotropin market statistics, including chorionic gonadotropin industry global market size, regional shares, competitors with a chorionic gonadotropin market share, detailed chorionic gonadotropin market segments, market trends and opportunities, and any further data you may need to thrive in the chorionic gonadotropin industry. This chorionic gonadotropin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The chorionic gonadotropin market consists of sales of products including follicle-stimulating hormone, luteinizing hormone, menotropins, gonadotropin-releasing hormone, and clomiphene citrate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Chorionic Gonadotropin Market Characteristics4. Chorionic Gonadotropin Market Trends and Strategies5. Chorionic Gonadotropin Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Chorionic Gonadotropin Market Pricing Analysis & Forecasts30. Global Chorionic Gonadotropin Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Chorionic Gonadotropin Market32. Recent Developments in the Chorionic Gonadotropin Market
3. Chorionic Gonadotropin Market Biologic Drug Characteristics
6. Global Chorionic Gonadotropin Growth Analysis and Strategic Analysis Framework
8. Chorionic Gonadotropin Market Segmentation
9. Global Chorionic Gonadotropin Market Epidemiology of Clinical Indications
10. Chorionic Gonadotropin Market Regional and Country Analysis
11. Asia-Pacific Chorionic Gonadotropin Market
12. China Chorionic Gonadotropin Market
13. India Chorionic Gonadotropin Market
14. Japan Chorionic Gonadotropin Market
15. Australia Chorionic Gonadotropin Market
16. South Korea Chorionic Gonadotropin Market
17. Western Europe Chorionic Gonadotropin Market
18. UK Chorionic Gonadotropin Market
19. Germany Chorionic Gonadotropin Market
20. France Chorionic Gonadotropin Market
21. Eastern Europe Chorionic Gonadotropin Market
22. North America Chorionic Gonadotropin Market
23. USA Chorionic Gonadotropin Market
24. Canada Chorionic Gonadotropin Market
25. South America Chorionic Gonadotropin Market
26. Middle East Chorionic Gonadotropin Market
27. Africa Chorionic Gonadotropin Market
28. Chorionic Gonadotropin Market Competitive Landscape and Company Profiles
29. Global Chorionic Gonadotropin Market Pipeline Analysis
33. Chorionic Gonadotropin Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Chorionic Gonadotropin Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on chorionic gonadotropin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for chorionic gonadotropin? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chorionic gonadotropin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Human Chorionic Gonadotropin; Animal Chorionic Gonadotropin2) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) by Therapeutic Application: Male Hypogonadism; Female Infertility Treatment; Oligospermic Treatment; Cryptorchidism Treatment; Chronic Pain; Other Therapeutic Applications
4) by End User: Research Institutions; Pharmaceutical Companies
Key Companies Mentioned: Ferring Pharmaceuticals
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Ferring Pharmaceuticals
